Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy

Applied Immunohistochemistry and Molecular Morphology

Volumn 15, Issue 3, 2007, Pages 325-331

  Phillips, Therese ^a   Murray, Gretchen ^a   Wakamiya, Karen ^a   Askaa, Jon ^a   Huang, Dennis ^a   Welcher, Rosanne ^a   Pii, Kurt ^a   Allred, D Craig ^b  

^a AGILENT TECHNOLOGIES   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Estrogen receptor (ER); Immunohistochemistry (IHC); Progesterone receptor (PR)

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; TEMPERATURE SENSITIVITY;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; NEOPLASMS, HORMONE-DEPENDENT; PATIENT SELECTION; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 34548245604     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000213135.16783.bc     Document Type: Article

References (18)

1. Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Intl J Cancer. 2000;89:111-117.
2. Fitzgibbons FK, Page DL, Weaver D, et al. Prognostic factors in breast cancer: College of American Pathologists consensus statement 1999. Arch Pathol Lab Med. 2000;124:966-978.
3. Bardou V-J, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21:1973-1979.
4. Elledge RM, Fuqua SAW. Ch. 31: Estrogen and progesterone receptors. In: Harris JR, ed. Diseases of the Breast. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000:471-473.
5. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168.
6. Diaz LK, Sneige N. Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol. 2005;12:10-19.
7. Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000;53:125-130.
8. Rhodes A, Jasani B, Balaton AJ, et al. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol. 2000;53:688-696.
9. Rhodes A, Jasani B, Balaton AJ, et al. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol. 2000;53:292-301.
10. Umemura S, Osamura RY. Utility of immunohistochemistry in breast cancer practice. Breast Cancer. 2004;11:334-338.
11. Layfield LJ, Gupta D, Mooney EE. Assessment of tissue estrogen and progesterone receptor levels: a survey of current practice, techniques, and quantitation methods. Breast J. 2000;6:189-196.
12. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481.
13. Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004;17: 1545-1554.
14. Leake R, Barnes D, Pinder S, et al. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. J Clin Pathol. 2000;53:634-635.
15. Al Saati T, Clamens S, Cohen-Knafo E, et al. Production of monoclonal antibodies to human estrogen-receptor protein (ER) using recombinant ER (RER). Int J Cancer. 1993;55: 651-654.
16. Press M, Spaulding B, Groshen S, et al. Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroids. 2002;67:799-813.
17. Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer. Am J Clin Pathol. 2005;123:16-20.
18. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5993 breast cancers. Am J Clin Pathol. 2005; 123:21-27.